<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Antineoplastons,Amino acid,Apoptosis,DNA methylation,Histone deacetylase,Oncogenes,P21,P53,Peptides,Phenylacetate,RAS" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Antineoplastons - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Antineoplastons</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <p><b>Antineoplastons</b> (ANP) are naturally-occurring <a href="../../../p/e/p/Peptides.html" title="Peptides">peptides</a> and <a href="../../../a/m/i/Amino_acid.html" title="Amino acid">amino acid</a> derivatives which are used to control the growth of cancer.</p>
<p>In 1967 <a href="../../../s/t/a/Stanislaw_Burzynski_e45f.html" title="Stanislaw Burzynski">Stanislaw Burzynski, M.D., Ph.D.</a> began investigating the use of antineoplastons after noting significant peptide deficiencies in the blood of cancer patients as compared with a control group<sup id="_ref-0" class="reference"><a href="#_note-0" title="">[1]</a></sup>.</p>
<p>Burzynski initially derived antineoplastons from human blood. Since similar peptides had been isolated from urine, in 1970 Burzynski switched to urine as a cheaper source of antinoeplastons. Since 1980 he has been reproducing antineoplastons synthetically<sup id="_ref-1" class="reference"><a href="#_note-1" title="">[2]</a></sup>.</p>
<p>Since his initial discovery, Burzynski has isolated dozens of peptide fractions from urine, some of which have been found to be active against cancer with low toxicity.</p>
<p>The first active peptide fraction identified was called antineoplaston A-10 (3-phenylacetylamino-2,6-piperidinedione). From A-10, antineoplaston AS2-1, a 4:1 mixture of <a href="../../../p/h/e/Phenylacetate.html" title="Phenylacetate">phenylacetate</a> and phenylacetylglutamine, was derived <sup id="_ref-2" class="reference"><a href="#_note-2" title="">[3]</a></sup>. The active ingredient of antineoplaston A10-I is phenylacetylglutamine <sup id="_ref-mechanism_0" class="reference"><a href="#_note-mechanism" title="">[4]</a></sup>. Current research is being conducted using these compounds alone or in combination.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Burzynski_Clinic_and_Research_Institute"><span class="tocnumber">1</span> <span class="toctext">Burzynski Clinic and Research Institute</span></a></li>
<li class="toclevel-1"><a href="#Treatment_with_Antineoplastons"><span class="tocnumber">2</span> <span class="toctext">Treatment with Antineoplastons</span></a></li>
<li class="toclevel-1"><a href="#Proposed_Mechanism_of_Action"><span class="tocnumber">3</span> <span class="toctext">Proposed Mechanism of Action</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">4</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1"><a href="#Burzynski_Clinic_Links"><span class="tocnumber">5</span> <span class="toctext">Burzynski Clinic Links</span></a></li>
<li class="toclevel-1"><a href="#External_Links"><span class="tocnumber">6</span> <span class="toctext">External Links</span></a></li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="Burzynski_Clinic_and_Research_Institute" id="Burzynski_Clinic_and_Research_Institute"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/t/Antineoplastons.html" title="Edit section: Burzynski Clinic and Research Institute">edit</a>]</span> <span class="mw-headline">Burzynski Clinic and Research Institute</span></h2>
<p>Today, Burzynski maintains corporate offices and operates a clinic in Houston, Texas where he treats patients with antineoplastons. At a nearby facility in Stafford, Texas he conducts research and manufactures the pharmaceutical ingredients used in the medications and other products that he produces.</p>
<p>Antineoplastons are being used in a line of skin care products and dietary supplements marketed by <a href="http://aminocare.com" class="external text" title="http://aminocare.com" rel="nofollow">Aminocare</a>, a division of the Burzynski Research Institute. FDA approval is currently being sought to sell an antineoplaston-derived dietary supplement designed to boost brain function.</p>
<p><a name="Treatment_with_Antineoplastons" id="Treatment_with_Antineoplastons"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/t/Antineoplastons.html" title="Edit section: Treatment with Antineoplastons">edit</a>]</span> <span class="mw-headline">Treatment with Antineoplastons</span></h2>
<p>Patients receiving cancer treatment with antineoplastons must first qualify for one of the <a href="http://clinicaltrials.gov/ct/search;?term=Antineoplastons" class="external text" title="http://clinicaltrials.gov/ct/search;?term=Antineoplastons" rel="nofollow">currently available clinical trials</a>. In order to qualify for most of the trials, a patient must have first failed standard treatment for the condition being treated, or it must be a condition that is unlikely to respond to currently available therapy and for which no curative therapy exists.</p>
<p>Antineoplastons may be administered intravenously or orally. Patients who respond positively to initial treatment with intravenous antineoplastons sometimes transition to the oral form.</p>
<p>Intravenous antineoplastons are administered continuously with a portable programmable pump that the patient carries on a shoulder strap in a canvas bag.</p>
<p>Treatment with antineoplastons can be very costly to patients without insurance coverage, exceeding $100,000 for the first year of intravenous treatment. Many insurance companies consider antineoplaston therapy to be investigational and unproven and will not cover the cost <sup id="_ref-3" class="reference"><a href="#_note-3" title="">[5]</a></sup><sup id="_ref-4" class="reference"><a href="#_note-4" title="">[6]</a></sup></p>
<p><a name="Proposed_Mechanism_of_Action" id="Proposed_Mechanism_of_Action"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/t/Antineoplastons.html" title="Edit section: Proposed Mechanism of Action">edit</a>]</span> <span class="mw-headline">Proposed Mechanism of Action</span></h2>
<p>Although the exact mechanism of action of antineoplastons is still not completely understood, there have been several discoveries that may explain their antitumor properties.</p>
<p>One of the factors that allows some cancers to grow out of control is the presence of abnormal enzymes, a byproduct of <a href="../../../d/n/a/DNA_methylation_b466.html" title="DNA methylation">DNA methylation</a>. In the presence of these enzymes, the normal life cycle of the cells is disrupted and they replicate continuously. Antineoplastons have been shown in the laboratory to inhibit these enzymes <sup id="_ref-5" class="reference"><a href="#_note-5" title="">[7]</a></sup>.</p>
<p>Recent studies have shown that inhibiting <a href="../../../h/i/s/Histone_deacetylase.html" title="Histone deacetylase">histone deacetylase</a> (HDAC) promotes the activation of <a href="../../../t/u/m/Tumor_suppressor_gene.html" title="Tumor suppressor gene">tumor suppressor genes</a> <a href="../../../p/2/1/P21.html" title="P21">p21</a> and <a href="../../../p/5/3/P53.html" title="P53">p53</a>. The active ingredient of antineoplaston AS2-1 and <a href="../../../s/o/d/Sodium_phenylbutyrate.html" title="Sodium phenylbutyrate">phenylbutyrate</a> have been shown to be weak HDAC inhibitors<sup id="_ref-6" class="reference"><a href="#_note-6" title="">[8]</a></sup>.</p>
<p>In normal cells, <a href="../../../r/a/s/RAS_5879.html" title="RAS">RAS</a> <a href="../../../o/n/c/Oncogenes.html" title="Oncogenes">oncogenes</a> express proteins that act as a switch to regulate cell growth. In about 30% of human cancers, RAS oncogenes contain abnormal mutations that cause proteins be overexpressed, giving rise to uncontrolled cell growth. Antineoplaston AS2-10 binds to the cells, preventing them from growing in response to the protein signals <sup id="_ref-7" class="reference"><a href="#_note-7" title="">[9]</a></sup>.</p>
<p>Burzynski explains that antineoplastons A10 and AS2-1 both work by inhibiting oncogenes, promoting <a href="../../../a/p/o/Apoptosis.html" title="Apoptosis">apoptosis</a>, and activating tumor suppressor genes <sup id="_ref-mechanism_1" class="reference"><a href="#_note-mechanism" title="">[4]</a></sup>.</p>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/t/Antineoplastons.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<ol class="references">
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> S.R. Burzynski, Antineoplastons: History of the Research (I)., Drugs Exp Clin Res. 1986;12 Suppl 1:1-9 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3527634" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3527634">PMID 3527634</a></li>
<li id="_note-1"><b><a href="#_ref-1" title="">^</a></b> Ralph Moss (1996), <i>The Cancer Industry</i> <a href="../../../b/o/o/Special%7EBooksources_ed7b.html" class="internal">ISBN 1881025098</a></li>
<li id="_note-2"><b><a href="#_ref-2" title="">^</a></b> NCI Drug Dictionary, <a href="http://cancer.gov/Templates/drugdictionary.aspx?searchTxt=antineoplaston" class="external text" title="http://cancer.gov/Templates/drugdictionary.aspx?searchTxt=antineoplaston" rel="nofollow">Definitions of antineoplastons A10 and AS2-1</a></li>
<li id="_note-mechanism">^ <a href="#_ref-mechanism_0" title=""><sup><i><b>a</b></i></sup></a> <a href="#_ref-mechanism_1" title=""><sup><i><b>b</b></i></sup></a> S.R. Burzynski, <a href="http://burzynskiclinic.com/assets/documents/ANP_mechamism_of_activity.pdf" class="external text" title="http://burzynskiclinic.com/assets/documents/ANP_mechamism_of_activity.pdf" rel="nofollow">The Proposed Mechanism of Antitumor Activity of Antineoplastons (ANPs) in High Grade Glioma Pathology (HBSG)</a> Integrative Cancer Therapies 2006; 40-47</li>
<li id="_note-3"><b><a href="#_ref-3" title="">^</a></b> Aetna Clinical Policy Bulletin, <a href="http://aetna.com/cpb/medical/data/200_299/0240.html" class="external text" title="http://aetna.com/cpb/medical/data/200_299/0240.html" rel="nofollow">Antineoplaston Therapy and Sodium Phenylbutyrate</a></li>
<li id="_note-4"><b><a href="#_ref-4" title="">^</a></b> Blue Cross/Blue Shield Medical Policy, <a href="http://empireblue.com/provider/noapplication/f2/s5/t9/pw_ad084920.pdf" class="external text" title="http://empireblue.com/provider/noapplication/f2/s5/t9/pw_ad084920.pdf" rel="nofollow">Antineoplaston Therapy</a></li>
<li id="_note-5"><b><a href="#_ref-5" title="">^</a></b> Ming C. Liau, S.R. Burzynski, Altered Methylation Complex Isozymes as Selective Targets for Cancer Chemotherapy, Drugs Exp Clin Res. 1986;12 Suppl 1:77-86. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3743383" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3743383">PMID 3743383</a></li>
<li id="_note-6"><b><a href="#_ref-6" title="">^</a></b> Manfred Jung, Inhibitors of Histone Deacetylase as New Anticancer Agents], Curr Med Chem. 2001 Oct;8(12):1505-11 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11562279" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11562279">PMID 11562279</a></li>
<li id="_note-7"><b><a href="#_ref-7" title="">^</a></b> Terri Mitchell, <a href="http://lef.org/magazine/mag2004/may2004_report_mystery_01.htm" class="external text" title="http://lef.org/magazine/mag2004/may2004_report_mystery_01.htm" rel="nofollow">Unlocking the Mystery of Antineoplastons</a>, Life Extension Magazine, May 2004</li>
</ol>
<p><a name="Burzynski_Clinic_Links" id="Burzynski_Clinic_Links"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/t/Antineoplastons.html" title="Edit section: Burzynski Clinic Links">edit</a>]</span> <span class="mw-headline">Burzynski Clinic Links</span></h2>
<ul>
<li><a href="http://burzynskiclinic.com" class="external text" title="http://burzynskiclinic.com" rel="nofollow">Burzynski Clinic</a></li>
<li><a href="http://burzynskiresearch.com" class="external text" title="http://burzynskiresearch.com" rel="nofollow">Burzynski Research Institute</a></li>
<li><a href="http://burzynskipatientgroup.com" class="external text" title="http://burzynskipatientgroup.com" rel="nofollow">Burzynski Patient Group</a></li>
<li><a href="http://groups.yahoo.com/group/antineoplastons" class="external text" title="http://groups.yahoo.com/group/antineoplastons" rel="nofollow">Antineoplastons Online Support Group</a></li>
</ul>
<p><a name="External_Links" id="External_Links"></a></p>
<h2><span class="editsection">[<a href="../../../a/n/t/Antineoplastons.html" title="Edit section: External Links">edit</a>]</span> <span class="mw-headline">External Links</span></h2>
<ul>
<li>Ralph W. Moss Ph.D., <a href="http://ralphmoss.com/burzynski.html" class="external text" title="http://ralphmoss.com/burzynski.html" rel="nofollow">The Burzynski Saga</a>, <i>The Cancer Chronicles</i> 1989-1996.</li>
<li>Michael Lerner, Ph.D, <a href="http://commonweal.org/pubs/choices/21.html" class="external text" title="http://commonweal.org/pubs/choices/21.html" rel="nofollow">Choices In Healing: Integrating The Best of Conventional and Complementary Approaches to Cancer</a>, 1994; 21:5, Cambridge, MIT Press</li>
<li><a href="http://caonline.amcancersoc.org/cgi/reprint/33/1/57.pdf" class="external text" title="http://caonline.amcancersoc.org/cgi/reprint/33/1/57.pdf" rel="nofollow">Antineoplastons</a>, <i>CA Cancer J Clin</i> 1983;33;57-59</li>
<li>Office of Technology Assessment, <a href="http://www.wws.princeton.edu/ota/disk2/1990/9044/904407.PDF" class="external text" title="http://www.wws.princeton.edu/ota/disk2/1990/9044/904407.PDF" rel="nofollow">Pharmologic and Biologic Treatments</a>, <i>Unconventional Cancer Treatments</i> Sept. 1990; Chapter 5:91-95</li>
<li>The Musella Foundation, <a href="http://virtualtrials.com/noteworth.cfm" class="external text" title="http://virtualtrials.com/noteworth.cfm" rel="nofollow">Clinical Trials and Noteworthy Treatments for Brain Tumors</a></li>
</ul>

<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/n/t/Antineoplastons.html">http://en.wikipedia.org../../../a/n/t/Antineoplastons.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../c/h/e/Category%7EChemotherapeutic_agents_0a44.html" title="Category:Chemotherapeutic agents">Chemotherapeutic agents</a></span> | <span dir='ltr'><a href="../../../p/r/o/Category%7EProdrugs_9e99.html" title="Category:Prodrugs">Prodrugs</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/n/t/Antineoplastons.html">Article</a></li><li id="ca-talk"
	       class="new"	       ><a href="../../../a/n/t/Talk%7EAntineoplastons_ee44.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Antineoplastons">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 21:31, 8 March 2007 by Wikipedia user <a href="../../../w/e/b/User%7EWebwench_1148.html" title="User:Webwench">Webwench</a>. Based on work by Wikipedia user(s) Ixelles and <a href="../../../s/t/b/User%7ESTBotT_9f5c.html" title="User:STBotT">STBotT</a> and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
